Showing results (1-10 of 315) with videos related to
Sort By:
Pageof 32
International Journal of Cardiology. Heart & Vasculature|April 10, 2019
Bound to bleed: How altered albumin binding may dictate warfarin treatment outcomeAnke C Fender, Dobromir DobrevThe Canadian Journal of Cardiology|April 8, 2026
Thrombo-inflammation in cardiometabolic diseaseAnke C Fender, Dobromir DobrevInternational Journal of Cardiology. Heart & Vasculature|December 22, 2021
Direct oral anticoagulation and severe obesity - One size fits all?Anke C Fender, Monika Gawalko, Dobromir DobrevPharmacological Research|May 6, 2019
Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulantsAnke C Fender, Reza Wakili, Dobromir DobrevCardiovascular Research|November 26, 2025
Type 1 diabetes mellitus and atrial fibrillation: clinical relationships, mechanistic insights, and therapeutic implicationsFlorian Bruns, Anke C Fender, Theresa Poppenborg, et al.Journal of Molecular and Cellular Cardiology|March 8, 2025
A short history of the atrial NLRP3 inflammasome and its distinct role in atrial fibrillationTheresa Poppenborg, Arnela Saljic, Florian Bruns, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|April 23, 2024
Ischemia does not provoke the full immune training repertoire in human cardiac fibroblastsConstantin Mann, Carolin van Alst, Simone Gorressen, et al.Basic Research in Cardiology|January 9, 2020
Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heartAnke C Fender, Sonja Kleeschulte, Svenja Stolte, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|April 23, 2024
The thrombin receptor PAR4 supports visceral adipose tissue inflammationSonja Kleeschulte, Vivien Fischinger, Lisa Öhlke, et al.British Journal of Pharmacology|May 18, 2024
Direct neuronal protection by the protease-activated receptor PAR4 antagonist ML354 after experimental stroke in miceMichael Fleischer, Rebecca D Szepanowski, Valeria Pesara, et al.Pageof 32